SECsense Logo

Arbutus Biopharma's 8-K Report: Key Updates for Investors on February 24, 2025

$ABUS
Form 8-K
Filed on: 2025-02-25
Source
Arbutus Biopharma's 8-K Report: Key Updates for Investors on February 24, 2025

Based on the provided financial report section, here are the key pieces of information:

  1. Filing Type: The document refers to a Form 8-K, which is typically used by publicly-traded companies to report major events that shareholders should know about.
  2. Entity Information:
  • Company Name: Arbutus Biopharma Corporation
  • CIK (Central Index Key): 0001447028
  • IRS Employer Identification Number (EIN): 98-0597776
  • Address: 701 Veterans Circle, Warminster, PA 18974
  • Contact Number: 267-469-0914
  • Ticker Symbol: ABUS
  • Exchange: NASDAQ
  1. Reporting Period: The report covers a specific date:
  • Date of Report: February 24, 2025
  1. Share Information:
  • Common Shares: The company has common shares without par value.
  • Units of Measurement: Financial figures are reported in USD (U.S. Dollars) and shares.
  1. Context and Structure:
  • The data is structured in XBRL (eXtensible Business Reporting Language), which is used for the electronic filing of financial reports.
  • The schema reference indicates that the document adheres to a specific set of standards and definitions.

Insights:

  • The report indicates that Arbutus Biopharma Corporation is actively reporting a significant event as per SEC regulations, which could be important for investors and stakeholders to monitor.
  • The specific date of reporting suggests that it may relate to a recent event or development within the company, warranting attention from analysts and investors.
  • Since this filing is a Form 8-K, it is crucial for stakeholders to review the specific event or information disclosed in this filing to understand its impact on the company's operations, financial health, or market perception.

Overall, this 8-K filing provides essential information about Arbutus Biopharma Corporation's recent activities and should be analyzed in the context of its broader financial reporting and market performance.